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Patients undergoing non-cardiac vascular surgery have arterial disease affecting more than one vascular bed and com-
monly have multiple significant co-morbidities. The surgical and anaesthetic teams are asked to address pre-, peri- and
postoperative management issues relating not only to the surgery but arising from these co-morbidities. Here we review
the strategies and rationale for the optimisation of these high risk patients.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Patients presenting for major non-cardiac vascular
surgery (NCVS) represent a dynamic challenge for the
anaesthetist and the surgeon that extends beyond the
intricacies of the planned operation. These patients
frequently have arterial disease affecting several vascu-
lar beds and suffer fromother significant co-morbidities
such as diabetes, respiratory and renal disease. The
management of these patients has to address not only
immediate perioperative management issues but also
prevent the deterioration of coexisting disease.
Assessing Perioperative Risk
Scoring systems such as POSSUM and P-POSSUM use
pre- and peri-operative data to calculate the probabil-
ity of an adverse outcome thus are of no value for pre-
operative risk prediction. The ASA (American Society
of Anaesthesiologists) score is shown in Table 1. This
seemingly crude score offers a means of formalising
the clinician’s subjective pre-operative assessment
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the patient’s preoperative status. However, it has been
shown to correlate well with the incidence of post
operative complications and death.1
Cardiovascular complications are a particular con-
cern in patients undergoing major NCVS. There are
a number of scoring systems directed towards estimat-
ing the risk of perioperative cardiovascular complica-
tions. Amongst the first was developed by Goldman
et al. which included 9 specific risk factors.2 However
this index has statistical flaws due to the number of
risk factors studied and a study population which suf-
fered a small number of cardiovascular complications.
Subsequent studies have attempted to refine the
original Goldman Risk Index but has been superseded
by the revised Cardiac Risk Index Score published in
1999.3 This was derived from a study of 2893 patients
and validated in a further 1422 patients. It includes
the risk factors listed in Table 2. Each risk factor is
allocated 1 point. The total points score gives an esti-
mate of perioperative cardiac risk. It is more robust
than the Goldman Risk Index as the study population
had a larger number of cardiac events and the authors
were more general in their definition of cardiac risk
factors.
Although a substantial step forward the revised
Cardiac Risk Index remains an imperfect tool and
does not perform well in certain subsets of patientsar Surgery. Published by Elsevier Ltd. All rights reserved.
626 S. J. Howell and R. S. Vohraundergoing NCVS, in particular those undergoing
aortic surgery. This issue is addressed by the Custom-
ised Probability Index developed in a cohort of 2310
patients undergoing elective NCVS over a ten year pe-
riod.4 The resulting predictive model is more complex
but appears to be specifically applicable to patients
undergoing vascular surgery (Fig. 1).
It should be noted that these tools are valuable for
adjusting for case mix when studying outcomes in sur-
gical populations but are of limited value for individual
risk predication. Unfortunately the perfect tool to pre-
dict individual risk does not exist. The experienced
clinical team should not depend on statistics alone
but trust their own judgement and experience.
Perioperative Cardiac Complications
Cardiac complications are common in patients under-
going NCVS. This is in part related to the high inci-
dence of coronary artery disease in these patients.5
However the precise aetiology of perioperative myo-
cardial injury remains unclear. Studies in NCVS pa-
tients have demonstrated perioperative myocardial
infarction (MI) is associated with perioperative myo-
cardial ischemic burden as detected by Holter moni-
toring.6 This would suggest that perioperative MI is
the result of protracted myocardial ischemia. On the
Table 2. The Lee Risk Index. The risk factors (high-risk type of
surgery; history of ischemic heart disease; history of congestive
heart failure; history of cerebrovascular disease; preoperative in-
sulin treatment and preoperative serum creatinine >2.0 mg/dl







rate in the validation








I 0 2/488 0.4% (0.05e1.5)
II 1 5/567 0.9% (0.3e2.1)
III 2 17/258 6.6% (3.9e10.3)
IV 3 or more 12/109 11% (5.6e18.4)
Table 1. The American Society of Anesthesiologists (ASA) physi-
cal status classification system
ASA Score
1 A normal healthy patient
2 A patient with mild systemic disease
3 A patient with severe systemic disease
4 A patient with severe systemic disease that is a
constant threat to life
5 A moribund patient who is not expected to survive
without the operation
6 A declared brain-dead patient whose organs are
being removed for donor purposesEur J Vasc Endovasc Surg Vol 34, December 2007Fig. 1. Customized probability model for perioperative all-
cause mortality. The sum of the assigned scores relates to
predicated mortality based on this index. Taken from Kertai
et al. 2005.
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of patients who suffer perioperative MI there is evi-
dence of coronary artery plaque fissuring and rupture
with the development of coronary thrombosis.7
Whilst these pathological changes were not found in
all the patients studied, their incidence was similar
to that seen in patients that presented with clinical ev-
idence of MI and subsequent death. It has been pro-
posed that these two mechanisms may not occur in
isolation.8 Periods of protracted myocardial ischemia
at emergence from anaesthesia may be associated
with increased shear stress across the atherosclerotic
plaque in the coronary arteries leading to plaque in-
jury and coronary thrombosis.
Just as acute coronary syndromes (ACS) display
a spectrum of myocardial injury; a similar continuum
exists in the context of perioperative myocardial in-
jury. Many patients who do not suffer a clinically
evident perioperative event do display a degree of
perioperative cardiac troponin release following
NCVS. Six-month and five-year follow up of these pa-
tients show a significantly worse prognosis9,10 (Fig. 2).
In addition prognosis appears to correlate with the
level of cardiac troponin release.
It should be emphasised that not every patient who
displays perioperative cardiac troponin release can be
labelled as having suffered a perioperative MI. Car-
diac troponin release is not itself a diagnostic test for
MI.11 However, it is clear that perioperative troponin
release has prognostic implications and an aim of
perioperative management should be to attenuate or
avoid perioperative myocardial injury.
Fig. 2. Kaplan-Meier survival curves of NCVS patients di-
vided according to postoperative troponin level (cTn-I e
cardiac troponin-I; cTn-T e cardiac troponin-T). Taken
from Landesberg et al. 2003.Cardiovascular Stability
One would expect high risk patients with underlying
coronary artery disease to be at increased risk of myo-
cardial ischemia if they suffer perioperative cardiac
instability. In a study of 100 high risk patients approxi-
mately a quarter of ischemic episodes were preceded
by significant increases in heart rate, 15% proceeded
by increases in blood pressure and 8% by acute
decreases in blood pressure.12 Even an optimistic inter-
pretation of these data would suggest that the majority
of intraoperative episodes or myocardial ischemia can-
not be attributed to haemodynamic changes. However
historical data from Slogoff and Keats offer a warning
regarding cardiovascular instability.13 In a study of
patients undergoing coronary artery by-pass grafting
these authors demonstrated a significant association
between perioperative myocardial ischemia and
markedperioperativeMI. In this study one anaesthetist
paid little regard to heart rate control. This individual’s
patients had a 9-fold increased risk of myocardial in-
farction. Thus, whilst not all perioperative myocardial
ischemia can be attributed to cardiovascular instability,
these data suggests that marked instability may have
significant adverse effects.
Perioperative Beta-blockade
Two trials of perioperative beta-blockade are widely
quoted. Mangano and colleagues randomised 200 pa-
tients undergoing vascular and other major surgery to
receive atenolol or placebo pre-operatively and for 7
days post-operatively. Patients enrolled into the study
either had proven cardiovascular disease or two or
more risk factors for cardiovascular disease. The
study demonstrated an improved outcome at 6
months amongst patients who received atenolol.14 In
the study by Poldermans et al. patients were rando-
mised to receive bisoporol or standard care. In the
group who received bisoprolol this was started one
to two weeks prior to surgery and the dose was in-
creased to achieve adequate heart rate control. There
was a 10-fold reduction in the perioperative cardio-
vascular event rate amongst the patients who received
bisoprolol.15
Conclusive as the results appear both studies have
significant weaknesses. Mangano and colleagues
excluded 6 patients who died in hospital from their
analysis and, despite randomisation, there was a
higher incidence of pre-existing cardiovascular dis-
ease in the placebo group than in the atenolol group.14
The Poldermans study was conducted in an extremely
high-risk subset of vascular surgery patients. TheEur J Vasc Endovasc Surg Vol 34, December 2007
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factors, new inducible wall motion abnormality on
dobutamine stress echocardiography and no pre-
existing beta-blockade. Only some 110 patients out
of an initial study population of over 1300 patients
were randomised. This was an unblinded study that
did not use a placebo and the study was stopped early
because of the very large benefit seen from beta-
blockade. Some authorities have argued that this
benefit was implausibly large and the study was
terminated too early. Importantly subsequent studies
have not been able to reproduce the benefits seen in
these initial two studies.16,17
A recent meta-analysis examined the effects of
beta-blockade in over 2000 patients randomised in 8
trials and found no overall benefit of perioperative
beta blockade (odds ratio 0.78(95% CI: 0.33e1.78)).18
Furthermore, an observational study in over 900,000
patients suggested that low risk patients with a
revised Cardiac Risk Index score of 0 or 1 may
actually be at increased risk of post-operative compli-
cations if they receive beta-blockers.19
However, it may be unwise to completely dismiss
the role of perioperative beta-blockade. Evidence
supports that good heart rate control with beta-
blockade below the patients ischemic threshold leads
to a substantial reduction in perioperative myocar-
dial ischemia and perioperative cardiac troponin
release.20
Whilst the evidence for initiating perioperative
beta-blockade is equivocal there are clear data indicat-
ing that the withdrawal of beta-blockers prior to ma-
jor surgery is associated with an increased incidence
of cardiovascular morbidity and mortality.21
We suggest that patients with a primary indication
for beta-blockade regardless of surgery should be con-
sidered for beta-blockade on the strength of this med-
ical indication. This should be initiated at least 1 to 2
weeks before surgery to allow adequate heart rate
control and to allow adverse effects to become evident
and should be continued beyond the perioperative
period in order to offer long term survival benefit. Re-
cently published guidelines of the American College
of Cardiology and American Heart Association rec-
ommend that:
1. Beta blockers should be continued in patients un-
dergoing surgery who are receiving beta-blockers
to treat angina, symptomatic arrhythmias, hyper-
tension, or other ACC/AHA Class I guideline
indications.
2. Beta blockers should be given to patients undergo-
ing vascular surgery with proven cardiac ischemia
on preoperative testing.22Eur J Vasc Endovasc Surg Vol 34, December 2007Statins
There are a number of recent studies that suggest sta-
tin therapy may reduce the risk of perioperative MI.
In a small group of NCVS patients commenced on
atorvastatin versus placebo showed a significant re-
duction in immediate post-operative events.23 This is
further supported by a retrospective analysis of
a larger cohort of NCVS patients and a meta-analysis
of 8 studies.24,25 This evidence, whilst promising, is
not conclusive. Many of these studies are small and
the data collected over a long period during which
practices have changed significantly. This is an area
in which the results of large randomised control trials
are required to guide therapy.
Data from medical patients suggest that the with-
drawal of statin therapy may itself be associated
with adverse consequences. Heeschen and colleagues
studied patients admitted to hospital following
ACS.26 Interestingly cessation of statins pre-event
was associated with significantly poorer outcomes
when compared to those patients who continued on
statin therapy or those who had never been on a statin.
It is important to be cautious in extrapolating from
medical to surgical patients but these data mitigate
against withdrawing statins from patients undergoing
NCVS.
Anti-platelet Therapy
Aspirin is indicated as secondary cardiovascular pre-
vention in patients presenting with occlusive arterial
disease.27 While there is concern that anti-platelet
agents may exacerbate surgical bleeding there is no
evidence that this translates to an increased incidence
of adverse outcome in NCVS patients or preventing
the use of local anaesthetic techniques.28 Again
evidence from medical patients admitted to hospital
following ACS suggest that those patients who had
aspirin withdrawn prior to the event had worse
outcomes than those who either continued on aspirin
or who had never received aspirin therapy.29 Taken
together this data suggest that withdrawing aspirin
is inappropriate in the context of patients undergoing
NCVS.
The most appropriate course of action in patients
who are receiving the ADP antagonist clopidogrel is
unclear. This potent anti-platelet agent is associated
with an increased risk of surgical bleeding and in pa-
tients undergoing cardiac surgery its use increases the
transfusion requirement but does not itself have a
direct effect on outcome.30 The indication for clopido-
grel use varies and in practice the judgement as to
629Perioperative Management and Vascular Surgerywhether clopidogrel should be discontinued has to be
made on a case-by-case basis. It may certainly be
appropriate to continue clopidogrel in patients under-
going carotid endarterectomy and lower limb
re-vascularisation if strongly indicated. However,
clopidogrel precludes the use of spinal or epidural
anaesthesia or regional blockade techniques such as
deep cervical plexus blockade.
Coronary Artery Disease
There is unequivocal evidence that patients who have
undergone coronary re-vascularisation have a reduced
incidence of perioperative MI.31 However, it does not
follow that patients should undergo coronary re-
vascularisation to simply reduce perioperative risk.
Indeed the cumulative risk of coronary angiography,
coronary artery by-pass grafting and then NCVS out-
weighs the risk of simply preceding to NCVS.32
A recent interventional study showed no benefit to
randomised patients who had undergone operative
or percutaneous coronary re-vascularisation prior to
surgery compared to those who proceeded straight
to surgery.33 The current consensus is that it is inap-
propriate to undertake coronary revascularisation
simply to reduce the risk of subsequent non-cardiac
surgery. These interventions should be considered
only where there are indicated on there own merits.
Coronary angioplasty has been revolutionised by
the advent of coronary stents. However, the insertion
of a metal stent leaves a thrombogenic surface
within the coronary artery. There is evidence that
NCVS conducted soon after stent insertion is associ-
ated with a significantly increased risk of periopera-
tive MI34 and data suggested that this risk persisted
for at least 6 weeks after percutaneous coronary
intervention.35 Recent data suggests that a patient
may still remain at risk of perioperative myocardial
infarction for several months after stent insertion.
Certainly patients who have had a bare metal stent
inserted in the 3 months prior to surgery should
have clopidogrel continued if at all possible.36 Re-
endothelialization of drug eluting stents takes longer
and patients with a drug eluting stent inserted in the
previous 12 months should remain on clopidogrel
throughout the perioperative period if at all possible.
Aspirin should be continued throughout the perio-
perative period in these patients unless very
strongly contra-indicated. The perioperative manage-
ment of surgical patients who have undergone
recent coronary artery stenting is examined in depth
in an excellent review by Howard-Alpe and
colleagues.37Temperature
Perioperative hypothermia is associated with cate-
cholamine release and may produce tachycardia and
vasoconstriction producing increased afterload. It is
now well established that the active pursuit of normo-
thermia is associated with a reduced incidence of
perioperative myocardial ischemia.38 This has been
simplified by the advent of modern warming technol-
ogies such as forced air warming blankets, fluid
warmers and a covering of the exposed bowel where
this is possible.
Anaesthetic Technique: General Anaesthesia
There is no evidence that favours one anaesthetic
technique over another for the prevention of perio-
perative complications including MI. There is labora-
tory evidence that suggests that volatile anaesthetic
agents may offer cardioprotection by ischemic pre-
conditioning39 and opening of the K-ATP channel
in mitochondria.40 There is now some translational
evidence that this effect is seen in small cardiac
surgery cohorts but considerably more work is
required.41
Anaesthetic Technique: Neuroaxial Blockage
Despite numerous studies there is no evidence that
epidural or spinal anaesthesia reduces mortality in
patients undergoing NCVS. A meta-analysis did sug-
gest a significant benefit from neuroaxial blockade.42
However, subsequent examination of these data re-
vealed that this effect rested on 3 small studies with
adverse event rates in the control group of between
20 and 30%. If these studies were excluded the benefit
from neuroaxial blockade was lost.
Pre-operative Testing
There is no evidence that any static test of cardiovas-
cular function adds significantly to the predictive
value to clinical risk factors to patients undergoing
NCVS. There is an association between a poor ejection
faction measured by echocardiography and adverse
outcomes following surgery.43 However this test has
a high false negative rate and does not preclude left
ventricular disfunction under stress.
Dynamic tests are more predictive but are resource
hungry. These include exercise ECG, resting and
stress myoview scans and stress echocardiography.
The ACC/AHA guidelines recommend the selective
use of these tests in patients who are undergoingEur J Vasc Endovasc Surg Vol 34, December 2007
630 S. J. Howell and R. S. VohraNCVS, have cardiovascular risk factors and have
a limited functional capacity.43
There is an unequivocal association between poor
lung function tests and post operative pulmonary
complications. However poor performance on lung
function testing does not preclude major NCVS.44 In-
deed it is well reported that abdominal aortic surgery
may be performed on patients with a FEV1 or less
than 1 metre. At least as important as lung function
testing is the clinical status of the patient.45
Presently there are no clear guidelines for pre-
operative carotid artery imaging in patients undergo-
ing NCVS. The prevalence of asymptomatic internal
carotid artery stenosis (>70%) in patients with periph-
eral arterial disease or abdominal aortic aneurysms is
about 10%.46 However the incidence of stroke follow-
ing NCVS is less than 1%.47 The decision to image the
internal carotid artery is left to the clinicians discre-
tion and further work needs to be done on this area.
Conclusions
Patients presenting for vascular surgery have a com-
plex array of medical problems. The careful manage-
ment of these problems can improve outcome for
these patients and is part of the fascination of this spe-
ciality. Put simply there is more to vascular surgery
than vascular surgery.
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